Clinical trial
A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV
NCT00049166 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2002
- Completion date
- Not reported
- Enrollment
- 48 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
stage ii squamous cell carcinoma of the lip and oral cavity, stage ii squamous cell carcinoma of the oropharynx, stage iii squamous cell carcinoma of the lip and oral cavity, stage iii squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the oropharynx